GlassScriptPhysician profile
David J Dickoff
NPI 1548202484
$112,191.84
in general payments reported to CMS, 2019-2025
69 companies · $5,060 in 2025
The $5,060 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $23K · 2021: $7,484 · 2022: $8,599 · 2023: $8,148 · 2024: $2,606 · 2025: $5,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,426 · Consulting Fee: $3,820 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,501 · Travel and Lodging: $1,051 · Education: $16.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,425.65 |
| Consulting Fee | $3,820.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,501.00 |
| Travel and Lodging | $1,051.07 |
| Education | $16.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $46,402.90 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $24,552.21 | 2019-2023 | |
| Allergan, INC. | $10,536.87 | 2019-2021 | |
| Abbvie INC. | $5,312.94 | 2019-2025 | Vraylar, Duopa, Ubrelvy |
| Mdd US Operations, LLC | $3,866.82 | 2019-2023 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $3,782.45 | 2023-2025 | Hyqvia |
| Eisai INC. | $2,848.04 | 2019-2025 | |
| Boston Scientific Corporation | $1,990.99 | 2020-2024 | |
| Abbott Laboratories | $1,795.38 | 2021-2022 | |
| Biogen, INC. | $1,340.92 | 2019-2023 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $983.99 | 2019-2025 | |
| Pfizer INC. | $799.51 | 2021-2025 | |
| Emd Serono, INC. | $690.78 | 2019-2023 | Mavenclad |
| Lundbeck LLC | $419.18 | 2019-2023 | Rexulti |
| Kyowa Kirin, INC. | $375.77 | 2020-2023 | Nourianz |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dickoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.